High Court Clears Puberty Blockers Trial for Children 2026

The High Court has cleared the way for a clinical trial giving puberty blockers to children, dismissing a legal challenge from campaigners concerned about potential harms. The Pathways trial, led by King’s College London, will recruit over 220 children aged 11 to 16 starting August 1.

What the High Court Ruling Means for the Puberty Blockers Trial

Mr Justice Chamberlain refused the application for judicial review, stating that none of the claims had a realistic chance of success. He emphasized that each participant would undergo months of specialist assessment before enrollment, ensuring only children with a reasonable prospect of clinical benefit receive treatment.

This decision allows the trial to proceed, but opponents, including psychotherapist James Esses and Keira Bell, expressed deep disappointment. Bell, who detransitioned after taking puberty blockers as a teenager, called the ruling a tragedy.

Key Arguments from Both Sides

Supporters argue the trial is essential to gather evidence on the safety and efficacy of puberty blockers. The university stressed that particular care will be taken over participant safety. Opponents, including The Bayswater Group, contend the trial lacks sufficient prior evidence and raises ethical concerns about researching on minors.

How the Pathways Trial Will Work

The trial will involve children aged 11 to 16 who have been referred to gender identity services. Each child will be assessed over many months by specialist doctors before any treatment begins. The study aims to provide much-needed evidence on the effects of puberty blockers.

Recruitment starts August 1, with researchers closely monitoring participants throughout the study period. The court’s ruling allows the trial to move forward without delay, but ongoing ethical debates are likely to continue.

Key Takeaways from the Ruling

• High Court rejects judicial review, allowing trial to proceed.
• Participants will undergo extensive specialist assessment.
• Trial aims to gather evidence on puberty blocker safety and efficacy.
• Opponents plan to continue advocacy against the trial.
• KCL emphasizes patient safety as a priority.

FAQ

As the trial moves forward, the medical community will watch closely. The High Court’s decision marks a significant step in researching puberty blockers, balancing clinical evidence with ethical considerations.